Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| dexamethasone Intravitreal Implant | Experimental | Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10. |
|
| ranibizumab | Active Comparator | Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| dexamethasone Intravitreal Implant | Drug | Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye | BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening. | Baseline, 12 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Foveal Thickness Measured by Optical Coherence Tomography (OCT) in the Study Eye | OCT is a laser based non-invasive diagnostic system providing high-resolution imaging sections of the fovea (part of the retina) in the study eye after pupil dilation. A negative change from baseline indicates an improvement (less foveal thickness) and a positive change from baseline indicates a worsening (more foveal thickness). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Allergan | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arlington | Texas | United States | ||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27632215 | Background | Callanan DG, Loewenstein A, Patel SS, Massin P, Corcostegui B, Li XY, Jiao J, Hashad Y, Whitcup SM. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):463-473. doi: 10.1007/s00417-016-3472-1. Epub 2016 Sep 8. | |
| 33206392 |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Dexamethasone Intravitreal Implant | Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10. |
| FG001 | Ranibizumab | Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| ranibizumab | Drug | Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression. |
|
|
| Baseline, Month 12 |
| Change From Baseline in Total Area of Macular Leakage in the Study Eye Measured on Fluorescein Angiography (FA) | FA is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. A negative change from baseline indicates a decrease in leakage (improvement) and a positive change from baseline indicates an increase in leakage (worsening). | Baseline, Month 12 |
| Brussels |
| Belgium |
| Copenhagen | Denmark |
| Glostrup Municipality | Denmark |
| Paris | France |
| Ahaus | Germany |
| Tel Aviv | Israel |
| Udine | Italy |
| Nijmegen | Netherlands |
| Coimbra | Portugal |
| Pretoria | South Africa |
| Barcelona | Spain |
| London | England | United Kingdom |
| Rittiphairoj T, Mir TA, Li T, Virgili G. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2020 Nov 17;11(11):CD005656. doi: 10.1002/14651858.CD005656.pub3. |
| 30293228 | Derived | Chakravarthy H, Devanathan V. Molecular Mechanisms Mediating Diabetic Retinal Neurodegeneration: Potential Research Avenues and Therapeutic Targets. J Mol Neurosci. 2018 Nov;66(3):445-461. doi: 10.1007/s12031-018-1188-x. Epub 2018 Oct 6. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Dexamethasone Intravitreal Implant | Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10. |
| BG001 | Ranibizumab | Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number | Participants |
| |||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye | BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening. | Intent-to-Treat: all randomized patients | Posted | Mean | Standard Deviation | Letters | Baseline, 12 Months |
|
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Foveal Thickness Measured by Optical Coherence Tomography (OCT) in the Study Eye | OCT is a laser based non-invasive diagnostic system providing high-resolution imaging sections of the fovea (part of the retina) in the study eye after pupil dilation. A negative change from baseline indicates an improvement (less foveal thickness) and a positive change from baseline indicates a worsening (more foveal thickness). | Intent-to-Treat: all randomized patients | Posted | Mean | Standard Deviation | Microns | Baseline, Month 12 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Total Area of Macular Leakage in the Study Eye Measured on Fluorescein Angiography (FA) | FA is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. A negative change from baseline indicates a decrease in leakage (improvement) and a positive change from baseline indicates an increase in leakage (worsening). | Intent-to-Treat: all randomized patients | Posted | Mean | Standard Deviation | Square Millimeters (mm^2) | Baseline, Month 12 |
|
|
Not provided
Treatment emergent adverse events (TEAE) are reported and include all adverse events (AEs) and serious adverse events (SAEs) that began or worsened after study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Dexamethasone Intravitreal Implant | Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10. | 40 | 181 | 160 | 181 | ||
| EG001 | Ranibizumab | Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression. | 41 | 182 | 104 | 182 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Renal Failure Acute | Renal and urinary disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Cardiac Failure Congestive | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Basal Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Coronary Artery Disease | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Acute Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Chest Pain | General disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Hip Fracture | Injury, poisoning and procedural complications | MedDRA version 16.1 | Systematic Assessment |
| |
| Intraocular Pressure Increased | Investigations | MedDRA version 16.1 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Anaemia | Blood and lymphatic system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Angina Pectoris | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Atrial Fibrillation | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Cardiac Failure | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Diabetic Foot | Skin and subcutaneous tissue disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Endophthalmitis | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Renal Failure Chronic | Renal and urinary disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Wound Infection | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Abscess Limb | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Acute Myocardial Infarction | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Anal Abscess | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Bladder Transitional Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Cardiac Pacemaker Insertion | Surgical and medical procedures | MedDRA version 16.1 | Systematic Assessment |
| |
| Chronic Obstructive Pulmonary Disease | Respiratory, thoracic and mediastinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Colitis | Gastrointestinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Duodenal Ulcer Haemorrhage | Gastrointestinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Grand Mal Convulsion | Nervous system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Inguinal Hernia | Gastrointestinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Kidney Infection | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Leukocytosis | Blood and lymphatic system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Liposuction | Surgical and medical procedures | MedDRA version 16.1 | Systematic Assessment |
| |
| Local Swelling | General disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Lung Squamous Cell Carcinoma Metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Mantle Cell Lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Meningorrhagia | Nervous system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Myocardial Infarction | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Neoplasm Malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Open Angle Glaucoma | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Orthostatic Hypotension | Vascular disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Pericardial Effusion | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Pericarditis | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Post Procedural Haemorrhage | Injury, poisoning and procedural complications | MedDRA version 16.1 | Systematic Assessment |
| |
| Prostate Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Pyelonephritis | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Respiratory Depression | Respiratory, thoracic and mediastinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Rotator Cuff Syndrome | Musculoskeletal and connective tissue disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Sialoadenitis | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Spinal Fracture | Injury, poisoning and procedural complications | MedDRA version 16.1 | Systematic Assessment |
| |
| Squamous Cell Carcinoma of the Tongue | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Tendon Rupture | Injury, poisoning and procedural complications | MedDRA version 16.1 | Systematic Assessment |
| |
| Abdominal Pain | Gastrointestinal disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Diabetes Mellitus Inadequate Control | Metabolism and nutrition disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Myocardial Ischaemia | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Abdominal Wall Abscess | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Aortic Valve Stenosis | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Atypical Pneumonia | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Cerebrovascular Accident | Nervous system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Choroiditis | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Colon Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Convulsion | Nervous system disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Endometrial Hyperplasia | Reproductive system and breast disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Femoral Neck Fracture | Injury, poisoning and procedural complications | MedDRA version 16.1 | Systematic Assessment |
| |
| Generalised Oedema | General disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Haemorrhagic Stroke | Nervous system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Hand Fracture | Injury, poisoning and procedural complications | MedDRA version 16.1 | Systematic Assessment |
| |
| Humerus Fracture | Injury, poisoning and procedural complications | MedDRA version 16.1 | Systematic Assessment |
| |
| Hypertensive Crisis | Vascular disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Infected Bites | Infections and infestations | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Jaundice | Hepatobiliary disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Lacrimation Increased | Eye disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Metabolic Acidosis | Metabolism and nutrition disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Nephropathy | Renal and urinary disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Oedema | General disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Osteonecrosis | Musculoskeletal and connective tissue disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Pancreatic Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Peripheral Ischaemia | Vascular disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Peripheral Vascular Disorder | Vascular disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Post Procedural Haematoma | Injury, poisoning and procedural complications | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Pulmonary Oedema | Respiratory, thoracic and mediastinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Renal Failure | Renal and urinary disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Septic Shock | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Squamous Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 16.1 | Systematic Assessment |
| |
| Sudden Hearing Loss | Ear and labyrinth disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Transient Ischaemic Attack | Nervous system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Type 2 Diabetes Mellitus | Metabolism and nutrition disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Upper Gastrointestinal Haemorrhage | Gastrointestinal disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Ventricular Tachyarrhythmia | Cardiac disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Vitreous Haemorrhage | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Weight Decreased | Investigations | MedDRA version 16.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Conjunctival Haemorrhage | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Cataract | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Vitreous Haemorrhage | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Visual Acuity Reduced | Eye disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Cataract Subcapsular | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Vitreous Floaters | Eye disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Ocular Hypertension | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Eye Pain | Eye disorders | MedDRA version 16.1 | Non-systematic Assessment |
| |
| Diabetic Retinal Oedema | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Vitreous Detachment | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Punctate Keratitis | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Macular Oedema | Eye disorders | MedDRA version 16.1 | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA version 16.1 | Systematic Assessment |
| |
| Intraocular Pressure Increased | Investigations | MedDRA version 16.1 | Systematic Assessment |
|
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Therapeutic Area Head, | Allergan, Inc | 714-246-4500 | clinicaltrials@allergan.com |
| ID | Term |
|---|---|
| D008269 | Macular Edema |
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003907 | Dexamethasone |
| D002123 | Calcium Dobesilate |
| D000069579 | Ranibizumab |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |
| D001557 | Benzenesulfonates |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D001190 | Arylsulfonates |
| D017739 | Arylsulfonic Acids |
| D013451 | Sulfonic Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| >65 years |
|
| Male |
|
|
|